Cardiovascular disease drug improves LDL and HDL cholesterol levels

GPs could be handed a novel preventive treatment for cardiovascular disease after an experimental drug was shown to improve levels of LDL and HDL cholesterol in at-risk patients.

Atherosclerosis: research is focusing on HDL cholesterol (Photograph: SPL)
Atherosclerosis: research is focusing on HDL cholesterol (Photograph: SPL)

Evacetrapib, one of a new class of treatments called cholesteryl ester transfer protein (CETP) inhibitors, was shown to more than double levels of HDL cholesterol. Higher levels are thought to have a protective effect against CHD.

Researchers said the findings could lead to larger-scale human trials.

The challenge to prevent cardiovascular disease has led researchers to focus on HDL cholesterol. People with elevated HDL show reduced incidence of CHD, while those with cardiovascular risk factors such as obesity and diabetes have lower levels.

The researchers noted: ‘However, development of drugs that increase HDL cholesterol levels has been challenging and fraught with failures.’

A team led by Stephen Nicholls of the Cleveland Clinic in Ohio conducted an RCT to test the effects, safety and tolerability of evacetrapib.

They assigned 398 patients to receive either placebo, various dosages of evacetrapib alone or statin therapy with or without the new drug.

After just 12 weeks, patients on evacetrapib alone saw average reductions in LDL cholesterol of up to 40%, or 1.33mmol/L. In addition, those on the highest dose evacetrapib also saw a rise in HDL cholesterol of up to 132%, or 1.71mmol/L.

By contrast, LDL cholesterol rose by 3% and HDL cholesterol fell by 3% among patients on placebo.

Researchers found that LDL cholesterol fell even further among those on evacetrapib 100mg in combination with statin therapy, although there was no further rise in HDL cholesterol.

They concluded: ‘These preliminary findings suggest that evacetrapib could be administered with statins and may yield potentially clinically important incremental effects on lipoproteins.’

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

No plans to impose face-to-face GP appointment targets, Hancock tells BMA

No plans to impose face-to-face GP appointment targets, Hancock tells BMA

The government has no plans to impose face-to-face appointments targets on general...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

COVID-19 variants could force UK to revaccinate over next 2-3 years warns CMO

COVID-19 variants could force UK to revaccinate over next 2-3 years warns CMO

The UK's chief medical adviser has warned that new coronavirus variants may force...

BMA condemns 'fundamentally flawed' £20m weight management enhanced service

BMA condemns 'fundamentally flawed' £20m weight management enhanced service

The BMA has condemned a £20m weight management enhanced service as 'fundamentally...

GP contract update delivers extra PCN cash and £50m for new enhanced services

GP contract update delivers extra PCN cash and £50m for new enhanced services

An update to the GP contract agreement for 2021/22 has set out details of enhanced...

CQC rejects call for independent review to look at BAME bias in ratings

CQC rejects call for independent review to look at BAME bias in ratings

The CQC has rejected calls for an independent review of its ratings process to look...